Skip to content
Medical Health Aged Care

ASA Welcomes Improved Transparency for Private Health Members

Australian Society of Anaesthetists 2 mins read

The Bill aims to strengthen transparency and improve patients’ understanding of their healthcare and private health insurance arrangements. The ASA supports these objectives and looks forward to continuing to work constructively with the Department to ensure that that all information published on the Medical Costs Finder website is both meaningful and relevant to patients and anaesthetists alike.

Dr Vida Viliunas, President of the ASA, said the reforms represent an important opportunity to improve clarity in a system that many patients find confusing.

“Private health insurance premiums are a significant contributor to cost-of-living pressures for Australian families,” Dr Viliunas said. “Patients deserve clear, accurate information about what their insurance covers and how they can receive value from the premiums they pay.”

One of the key features of the Bill is its focus on increasing transparency around private health insurance products. The ASA believes this will help address longstanding confusion about coverage, out-of-pocket costs, and insurer arrangements.

The ASA recently commissioned an independent survey of more than 1,100 anaesthetists across Australia. The survey examined out-of-pocket costs, informed financial consent, private health insurance arrangements, patient access and equity.

The findings show that an overwhelming majority of anaesthetists use known-gap or no-gap arrangements wherever possible. However, the failure to index rebates and the cap on gap limits are making participation in these schemes increasingly difficult.

“When rebates are not indexed and gap limits are capped below the real cost of providing care, it becomes harder for doctors to sustainably participate in no-gap and known-gap schemes,” Dr Viliunas said. “These arrangements must adequately reflect the true costs of delivering safe, high-quality anaesthesia.”

The survey also confirmed that informed financial consent is already a routine part of anaesthetic practice, particularly for planned admissions such as elective surgery. A large majority of anaesthetists provide patients with clear information about likely fees and potential out-of-pocket costs, noting that these may vary depending on clinical complexity or procedure duration.

“Anaesthetists are committed to ensuring patients understand the likely financial implications of their care,” Dr Viliunas said. “We are hopeful that the changes proposed in the Bill will reflect the realities of clinical care and avoid reducing high-quality medical services to simplistic price-comparison tools.”

Importantly, the survey highlighted that many patients do not fully understand what their private health insurance policy covers - an issue that sits outside the control of anaesthetists, whose primary focus remains patient safety and clinical care.

The ASA supports greater transparency from private health insurers regarding what policies include, how agreements with providers operate, and how arrangements affect patients and hospitals.

“Improving transparency must involve insurers clearly explaining what is and is not covered,” Dr Viliunas said. “Patients should not be left navigating complexity alone.”

The Australian Society of Anaesthetists remains committed to working collaboratively with government and stakeholders to ensure reforms improve understanding, strengthen patient trust, and support the continued delivery of safe, high-quality anaesthetic care.


Contact details:

For further information:  Leon Beswick 0414 332 267

Media

More from this category

  • Business Company News, Medical Health Aged Care
  • 12/02/2026
  • 09:37
I-screen - an Australian-founded health technology company

Former AWS and Accenture AI Leader Joins Australian Healthtech i-screen as AI Push Accelerates

Key points High-profile global AI executive appointment signals next growth phase for Australian healthtech Brad Ryan appointed Chief AI Officer – Former AWS APJ Data & AI Partner Lead and Accenture Managing Director with 30+ years technology leadership experience Platform scale now approaching 1 million diagnostic tests across four countries Singapore expansion positions i-screen as a regional AI-driven preventive health player AI investment focused on earlier detection, personalised screening and longevity insights Australian-founded health technology company i-screen has appointed senior global technology executive Brad Ryan,GAICD, as Chief AI Officer, strengthening its leadership team as the business deepens its investment in…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 12/02/2026
  • 09:29
Private Healthcare Australia

Health funds back stronger transparency laws for specialist doctor fees

Private Healthcare Australia has welcomed the Federal Government’s legislation to upgrade the Medical Costs Finder website, saying it is a critical step toward tackling Australia’s growing specialist fee crisis. The reform will expand the information available about specialist doctors’ fees, allowing patients to compare typical costs before booking an appointment and better estimate their likely out-of-pocket expenses. The move comes after PHA last week released its report, Restoring affordable access to specialist care in Australia, backed by a nationally representative survey of more than 4,000 Australians. The report revealed an urgent affordability and access problem reshaping Australia’s health system. It…

  • Medical Health Aged Care
  • 12/02/2026
  • 09:00
Monash University

Monash University publishes a world first clinical practice guideline for the appropriate use of psychedelics

A new Australian Clinical Practice Guideline for the Appropriate Use of Methylenedioxymethamphetamine-assisted psychotherapy (MDMA-AP) for Post-Traumatic Stress Disorder (PTSD) has been approved by the National Health and Medical Research Council (NHMRC). The Guideline is the world’s first related to MDMA-AP to be developed using the gold standard Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. In 2023, Australia became the first country to reschedule MDMA from a Prohibited Substance (Schedule 9) to a Controlled Substance (Schedule 8) for the treatment of PTSD. This has allowed authorised psychiatrists to administer MDMA for the treatment of PTSD outside of clinical trials.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.